[Donepezil : a new option in the treatment of Alzheimer's disease] ONEPA.
Azanza
J R
JR
Servicio de Farmacología Clínica, Facultad de Medicina, Universidad de Navarra.
Sádaba
B
B
Quetglas
E G
EG
Escolar
M
M
D000109:Acetylcholine / Q000502:physiology; D000544:Alzheimer Disease / Q000188:drug therapy*; D001682:Biological Availability; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D019389:Cytochrome P-450 CYP2D6 / Q000378:metabolism; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D000077265:Donepezil; D004347:Drug Interactions; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006261:Headache / Q000139:chemically induced; D006801:Humans; D008658:Inactivation, Metabolic; D007189:Indans / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006899:Mixed Function Oxygenases / Q000378:metabolism; D018697:Nootropic Agents / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010880:Piperidines / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced; D014018:Tissue Distribution
D002800:Cholinesterase Inhibitors; D007189:Indans; D018697:Nootropic Agents; D010880:Piperidines; D000077265:Donepezil; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; C104464:CYP3A protein, human; D019389:Cytochrome P-450 CYP2D6; D051544:Cytochrome P-450 CYP3A; D000109:Acetylcholine
Donepezilo: una nueva opción en el tratamiento de la enfermedad de Alzheimer.